About

SignaBlok, Inc. is a Massachusetts-based biopharmaceutical startup. Using proprietary intellectual property and related breakthrough science, the Company is developing novel mechanism-based therapies and targeted delivery nanosystems for serious disorders with unmet clinical needs.

SignaBlok focuses on four core therapeutic areas: cancer (including lung, breast and pancreatic cancers), atherosclerosis, inflammatory and immune diseases, with the primary focus on cancer.

Additional information about SignaBlok is available at www.signablok.com.